Unicentric Castleman Disease

Watchlist

(log in to enable)

Retrieved

2022-04-26

Source

Gard

Trials

—

Genes

IL6, VEGFA, MLYCD, IL6R, MUC1, SMUG1, TLR4, CXCL13, LRPPRC, ABCG2, MYOM2, HMGA2, AR, ODC1, CD48, JAK1, IL6ST, IL1B, IL1A, HLA-C, FUT4, NM

Drugs

Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus, Humanised anti-human Interleukin-6 (IL-6) receptor monoclonal antibody (Genetic Recombination) ( ANTI-HUMAN INTERLEUKIN-6 (IL-6) RECEPTOR MONOCLONAL ANTIBODY (GENETICAL RECOMBINATION) CHUGAI PHARMACEUTICAL CO LTD ), Siltuximab ( SYLVANT ), haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate

Interested in hearing about new therapies?

Unicentric Castleman disease (UCD) is a rare condition that affects the lymph nodes and related tissues. It is a form of Castleman disease that is "localized" to a single set of lymph nodes (as opposed to multicentric Castleman disease which has more widespread effects). UCD often starts as an enlarged lymph node. Depending on the location of this enlarged node, some people will have no additional features of the condition, while others will develop symptoms when it pushes on nearby organs and/or tissues. The exact underlying cause of UCD is currently unknown. Treatment typically includes surgical removal of the affected lymph node.